With operations in more than 100 countries, the world’s largest CRO Quintiles is now looking to extend its global reach even farther, CEO Tom Pike told investors at the Barclays Global Healthcare Conference on Tuesday.
Strategic partnerships - always a hot-topic for CROs – are becoming almost exclusively a big issue for mid-sized biopharma, though small biopharma and large pharma companies are interested as well, Quintiles CEO Tom Pike said Monday at the Morgan Stanley...
Quintiles CEO Tom Pike told investors last week that the company is seeing “very strong demand from the larger pharmaceutical firms because their pipelines are full right now,” and at the same time, small biotech, with their plethora of funding, are starting...
CEO Tom Pike emphasised Quintiles’ credentials as a Big Pharma collaborator and highlighted personalised medicines as a key driver for the CRO at an investment conference last week.
CRO Quintiles last week announced its fourth consecutive quarter of at least $1B in net new business, as well as 13% growth in the second quarter of this year, though analysts said the company did not meet bookings expectations.
